Weight loss efficiency and safety of tirzepatide: A Systematic review
PLOS ONE · 04.05.2023 · 18 (5) · e0285197
DOI: 10.1371/journal.pone.0285197 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 04.05.2023. Verfasst von Fei Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2DM) and obesity patients in this meta-analysis study.
Methods
Cochrane Library, PubMed, Embase, Clinical Trials, and Web of Science were searched from inception to October 5, 2022. All randomized controlled trials (RCTs) were included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software.
Results
In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively. In sub-analysis, the body weight of patients was significantly reduced in three tirzepatide doses (5 mg, 10 mg, and 15 mg) when compared with those of the placebo/GLP-1 RA/insulin. In terms of safety, the incidence of any adverse events and adverse events leading to study drug discontinuation was higher in the tirzepatide group, but the incidence of serious adverse events and hypoglycaemia was lower. Additionally, the gastrointestinal adverse events (including diarrhea, nausea, vomiting and decreased appetite) of tirzepatide were higher than those of placebo/basal insulin, but similar to GLP-1 RAs.
Conclusion
In conclusion, tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- Clinical Medical College, Chengdu Medical College, Chengdu, China.
- Department of Pharmacy, Mianyang Central Hospital, Mianyang, China.
- School of Pharmacy, Chengdu Medical College, Chengdu, China.
- Department of Pharmacy, Binzhou Medical University Hospital, Binzhou, China.
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Ya…
Zitieren
APA
Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., & Li, Y. (2023). Weight loss efficiency and safety of tirzepatide: A Systematic review. PLOS ONE, 18(5), e0285197. https://doi.org/10.1371/journal.pone.0285197
Vancouver
Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, et al. Weight loss efficiency and safety of tirzepatide: A Systematic review. PLOS ONE. 2023;18(5):e0285197. doi:10.1371/journal.pone.0285197
BibTeX
@article{Lin2023,
author = {Lin, Fei and Yu, Bin and Ling, Baodong and Lv, Guangyao and Shang, Huijun and Zhao, Xia and Jie, Xiaoling and Chen, Jing and Li, Yan},
title = {Weight loss efficiency and safety of tirzepatide: A Systematic review},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {5},
pages = {e0285197},
doi = {10.1371/journal.pone.0285197}
}
EUVIMED